Akorn Inc (AKRX.O)
20 Oct 2017
Tue, Oct 3 2017
TEL AVIV, Oct 3 New York-based Senvest Management is shorting three drug stocks, Insys Therapeutics Inc , Akorn Inc and Fresenius SE, its chief executive Richard Mashaal said on Tuesday,
* At yesterday's special meeting, shareholders of Akorn, Inc., have approved merger agreement with fresenius kabi, with 83.9 percent of outstanding shares being voted in favour of transaction. Source text for Eikon: Further company coverage:
* Akorn shareholders vote to approve merger agreement with Fresenius Kabi
FRANKFURT German healthcare group Fresenius SE & Co KGaA has stepped up its dealmaking, agreeing to buy U.S. generic drugmaker Akorn Inc for $4.75 billion (4.37 billion euros) and the biosimilars arm of Germany's Merck KGaA.
* Fresenius shares up almost 1 percent (Adds advisers, shares, background, CEO, analyst comments)
* Akorn - deal with Fresenius Kabi provides under specified circumstances, co to be required to pay Fresenius Kabi AG termination fee of $129 million Source text: (http://bit.ly/2oEMWQV) Further company coverage:
FRANKFURT, April 24 Acquisitive German healthcare conglomerate Fresenius SE & Co KGaA revved up its deals pace by acquiring U.S. generic drugmaker Akorn Inc for $4.75 billion (4.37 billion euros), and in a separate deal, the biosimilars unit of German peer Merck KGaA .
German healthcare conglomerate Fresenius SE & Co KGaA is close to acquiring generic drugmaker Akorn Inc in an all-cash deal valuing the company at more than $4 billion, people familiar with the matter said on Monday.